Cytodyn Inc (CYDY)

[stockorus]

Key findings from a pooled analysis of efficacy data of 28 subjects with mTNBC, including those with brain or bone metastases, who had failed ≥ 2 lines of prior systemic therapies, are as follows:

The median overall survival (mOS) for patients that received higher doses (≥ 525 mg) of leronlimab plus chemotherapy was 12+ months (95% CI, 5.5 – 12+ months), which is superior to SOC chemotherapy (6.6 months) or Sacituzumab Govitecan (SG) (11.8 months), an antibody drug conjugate that received accelerated approval by the FDA in 2020 and regular approval in 2021 for the treatment of patients with unresectable locally advanced or mTNBC who have received ≥ 2 prior systemic therapies.

The article says both our patients and the SG patients had received 2 or more prior therapies. It says nothing about our patients being naive and SG patients being RR. You have any reference that says specifically SG trial was done mainly with RR patients? General statement on “most cancer trials” is speculation here for SG and LL.